JPMorgan Chase & Co. grew its stake in PetMed Express, Inc. (NASDAQ:PETS) by 213.2% during the third quarter, HoldingsChannel.com reports. The fund owned 36,499 shares of the company’s stock after acquiring an additional 24,844 shares during the period. JPMorgan Chase & Co.’s holdings in PetMed Express were worth $1,215,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PETS. Fuller & Thaler Asset Management Inc. acquired a new position in shares of PetMed Express in the third quarter valued at approximately $534,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of PetMed Express in the third quarter valued at approximately $149,000. Dynamic Technology Lab Private Ltd grew its holdings in shares of PetMed Express by 116.2% in the third quarter. Dynamic Technology Lab Private Ltd now owns 21,925 shares of the company’s stock valued at $727,000 after purchasing an additional 11,782 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of PetMed Express in the third quarter valued at approximately $577,000. Finally, Ameriprise Financial Inc. grew its holdings in shares of PetMed Express by 48.8% in the third quarter. Ameriprise Financial Inc. now owns 285,835 shares of the company’s stock valued at $9,474,000 after purchasing an additional 93,699 shares in the last quarter. 99.88% of the stock is currently owned by institutional investors and hedge funds.

PetMed Express, Inc. (PETS) opened at $51.68 on Friday. PetMed Express, Inc. has a twelve month low of $19.21 and a twelve month high of $52.20. The company has a market cap of $1,060.00, a P/E ratio of 34.68, a price-to-earnings-growth ratio of 2.87 and a beta of 1.12.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Monday, October 23rd. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million during the quarter, compared to analysts’ expectations of $63.41 million. During the same quarter in the previous year, the business posted $0.24 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. research analysts expect that PetMed Express, Inc. will post 1.68 earnings per share for the current year.

In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the completion of the transaction, the director now owns 73,833 shares in the company, valued at approximately $2,626,239.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the transaction, the director now owns 55,900 shares of the company’s stock, valued at approximately $2,480,842. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.

A number of research analysts recently weighed in on the stock. ValuEngine cut shares of PetMed Express from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Credit Suisse Group restated an “underperform” rating and issued a $19.00 price objective on shares of PetMed Express in a report on Monday, October 2nd. Northcoast Research set a $58.00 price objective on shares of PetMed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. Zacks Investment Research cut shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a report on Monday, September 25th. Finally, BidaskClub upgraded shares of PetMed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. PetMed Express currently has an average rating of “Hold” and a consensus target price of $42.80.

TRADEMARK VIOLATION NOTICE: “PetMed Express, Inc. (PETS) Shares Bought by JPMorgan Chase & Co.” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/petmed-express-inc-pets-shares-bought-by-jpmorgan-chase-co/1803969.html.

PetMed Express Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetMed Express, Inc. (NASDAQ:PETS).

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.